Hints and tips:
...Nick Jackson, who oversees vaccine R&D at the Coalition for Epidemic Preparedness Innovations, part of Covax, said it now feels “enormously relieved and quite vindicated” that it invested almost $400m in...
...To be fair, many have escaped to the seaside towns outside of New York City since the widespread coronavirus lockdowns in March, but few are getting R&R at the moment....
...“We want to add to our pipeline organically through our own R&D and through acquisitions,” he said, adding that the proceeds would not go to paying down debt....
...J&J said its consumer health division benefited from increased demand driven by the coronavirus pandemic, with sales rising 11 per cent in the quarter to $3.6bn....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.”...
...For instance, it paid $4.2bn of interest over the first six months of 2018 — more than the revenues of 259 of the S&P 500's constituents in the same period, according to S&P Capital IQ....
...A significant slowdown could, therefore, have a substantial impact on citizens’ financial health....
...H & R Block, meanwhile, was the biggest decliner on the benchmark index, tumbling nearly 19 per cent to $24.04 after issuing disappointing margin guidance....
...The swift unravelling of the toy seller, at $6.9bn the third-largest retail bankruptcy in history, jolted vendors, who are critical to a retailer’s health....
...In July, DWCP sold a portfolio worth more than $9.4bn to Guangzhou-based developer R&F as well as acquisitive property developer Sunac....
...But now the humble pakora — and its makers — have emerged at the heart of a passionate debate about India’s economic health....
...Health....
...And while R&D and marketing dollars have shifted up in recent years, Pepsi has wrung operating cost savings elsewhere, alongside tightening cash spend on working capital....
...R&D budgets at about $9bn a year....
...US earnings The US is nearly three quarters of its way through earnings season but more than 120 companies on the S&P 500 are slated to report results this week....
...Critics have accused GSK of turning away from R&D after its $20bn asset swap with Novartis deepened the company’s diversification into vaccines and consumer health....
...But Nike had good news, with shares rising 5 per cent to $120.68 in after hours trading on a strong profits beat. The S&P 500 fell 0.34 per cent to 1,932.24....
...This has left the company’s share price almost unchanged over the period while the S&P pharmaceuticals index has doubled....
...Downward pricing pressure hitherto associated with the cash-strapped public health systems of Europe has been spreading across the Atlantic, as the US gets serious about cutting waste from its private health...
...But they are joined by well-known US companies such as Weight Watchers, Toys R Us, Sears, and Advanced Micro Devices, a chipmaker....
...Whether the ex-JPMorgan executive’s performance will, in time, be hailed as a coup de theatre, depends largely on the health of Asian economies and the success with which Standard Chartered builds up its...
...Groups from Macy’s to Urban Outfitters have reported falling revenues and missed analysts’ estimates in recent days, pushing the S&P Retail Select Industry Index down 8.5 per cent last week to mark the sector...
...This optimism is reflected in the 40 per cent jump in the S&P pharmaceuticals index over the past year, compared with a 7 per cent rise in the broader S&P 500....
...Over the past five years CSL has invested US$2bn in R&D and employs more than 1,000 scientists....
International Edition